Can pharmaceutical companies profit from the therapeutic knowledge generated by the new university medical network on Covid-19 research?
University medicine, which is performed at a very high level in Germany, are another source of important ideas for Covid-19 treatments. Here, too, cooperative agreements are arranged to develop generally available products. University medicine is an essential partner for testing out medications for Covid-19 patients.
Are there pharmaceutical companies in Germany that don’t do research?
At present, there are 44 research based pharmaceutic companies in Germany. In addition there are firms with a palette of older medications and ones that exclusively produce generics.
Is it correct to talk about “German companies” in the age of globalization?
We should speak of pharmaceutical companies that do their work in Germany. They make Germany the pharmaceutical location that it is – one that plays a leading role internationally.
Do you believe the corona crisis will lead to a rethink within the pharmaceutical industry? For example, will companies locate more of their production in Germany?
Germany is one of the world’s strongest production locations where innovative, patented medications are concerned. Even amidst the stress test of the corona pandemic, Germany has remained capable of delivering and exports significantly more patented medications to China than it imports from that country. Our organization by no means stands in the way of a debate over whether more could be produced in Germany. But we go into the debate from a position of strength as far as the research-based pharmaceutical companies in Germany are concerned.
Why should foreign companies be interested in investing in this sector in Germany?
Germany enjoys a particularly good reputation for medical products, and that stands the country in good stead when demands are high, needs are complex and mistakes need to be avoided. In such situations, the advantages of Germany have their effect: a well-functioning infrastructure and an excellently trained workforce. These are all arguments for investing in the production of medical supplies in Germany.